These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 29309249)

  • 1. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
    Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
    Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
    Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; George DJ
    BMC Cancer; 2021 Aug; 21(1):904. PubMed ID: 34364385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
    Cella D; Escudier B; Tannir NM; Powles T; Donskov F; Peltola K; Schmidinger M; Heng DYC; Mainwaring PN; Hammers HJ; Lee JL; Roth BJ; Marteau F; Williams P; Baer J; Mangeshkar M; Scheffold C; Hutson TE; Pal S; Motzer RJ; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(8):757-764. PubMed ID: 29377755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
    Powles T; Motzer RJ; Escudier B; Pal S; Kollmannsberger C; Pikiel J; Gurney H; Rha SY; Park SH; Geertsen PF; Gross-Goupil M; Grande E; Suarez C; Markby DW; Arroyo A; Dean M; Choueiri TK; George D
    Br J Cancer; 2018 Sep; 119(6):663-669. PubMed ID: 30197417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
    Choueiri TK; Hessel C; Halabi S; Sanford B; Michaelson MD; Hahn O; Walsh M; Olencki T; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; George D; Morris MJ
    Eur J Cancer; 2018 May; 94():115-125. PubMed ID: 29550566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
    Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
    N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cabozantinib: Mechanism of action, efficacy and indications].
    Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
    Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
    Motzer RJ; Escudier B; Powles T; Scheffold C; Choueiri TK
    Br J Cancer; 2018 May; 118(9):1176-1178. PubMed ID: 29576624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
    Schmidinger M; Motzer RJ; Rolland F; Staehler M; Rink M; Retz M; Csoszi T; McCaffrey JA; De Giorgi U; Caserta C; Duran I; Benzaghou F; Clary DO; Albiges L; Choueiri TK; Tannir NM
    Acta Oncol; 2022 Jan; 61(1):52-57. PubMed ID: 34736367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
    Al-Salama ZT; Keating GM
    Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
    Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
    J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.
    Denize T; Farah S; Cimadamore A; Flaifel A; Walton E; Sticco-Ivins MA; Labaki C; Braun DA; Sun M; Wang E; Xie W; Choueiri TK; Signoretti S
    Clin Cancer Res; 2022 Feb; 28(4):748-755. PubMed ID: 34921022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
    Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
    J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.